Formycon

FYB.DE Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

€18.62

-1.79% today

52W: €15.80 – €31.30

52W Low: €15.80 Position: 18.2% 52W High: €31.30

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

6.85x

Price-to-Sales

EV/EBITDA

2.35x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$329.1M

Market Capitalization

Revenue Growth

-26.1%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

—

Return on Equity

Beta

0.67

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

17,133

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

7 analysts

Avg. Price Target

€40.71

+118.66% upside

Target Range

€30.00 – €53.00

About the Company

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin'

Sector: Healthcare Industry: Biotechnology Country: Germany Employees: 250 Exchange: GER